Overview

EPIC-Peds: Study of Oral PF-07321332 (Nirmatrelvir)/Ritonavir in Nonhospitalized COVID-19 Pediatric Patients at Risk for Severe Disease

Status:
Not yet recruiting

Trial end date:
2023-03-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety, pharmacokinetics, and efficacy of nirmatrelvir/ritonavir for the treatment of nonhospitalized, symptomatic pediatric participants with coronavirus disease 2019 (COVID-19) who are at risk of progression to severe disease.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Ritonavir